| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 10162127 | Journal of Pharmaceutical Sciences | 2015 | 10 Pages | 
Abstract
												Microfluidization is an established technique for preparing emulsion adjuvant formulations for use in vaccines. Although this technique reproducibly yields high-quality stable emulsions, it is complex, expensive, and requires proprietary equipment. For this study, we developed a novel and simple low shear process to prepare stable reproducible emulsions without the use of any proprietary equipment. We found this process can produce a wide range of differently sized emulsions based on the modification of ratios of oil and surfactants. Using this process, we prepared a novel 20-nm-sized emulsion that was stable, reproducible, and showed adjuvant effects. During evaluation of this emulsion, we studied a range of emulsions with the same composition all sized below 200; 20, 90, and 160 nm in vivo and established a correlation between adjuvant size and immune responses. Our studies indicate that 160-nm-sized emulsions generate the strongest immune responses.
											Keywords
												
											Related Topics
												
													Health Sciences
													Pharmacology, Toxicology and Pharmaceutical Science
													Drug Discovery
												
											Authors
												Ruchi R. Shah, Stephanie Dodd, Mary Schaefer, Mildred Ugozzoli, Manmohan Singh, Gillis R. Otten, Mansoor M. Amiji, Derek T. O'hagan, Luis A. Brito, 
											